FCGR2A and neuroblastoma: Notably, TAMs in high-risk neuroblastoma tissues highly expressed the macrophage-activating Fcγ receptor genes FCGR2A and FCGR3A (Figure S1D), and therefore, antibody-mediated approaches are plausible for treating high-risk neuroblastoma patients.